Liraglutide: Evidence, Mechanism, Dosing & Legal Status

Liraglutide (marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management) is a once-daily injectable GLP-1 receptor agonist — an acylated, incretin-mimetic analog of human GLP-1.1 Unlike most peptides discussed in fitness and longevity circles, its claims do not rest on extrapolation: liraglutide is backed by tens of thousands of randomized participants and a dedicated outcomes trial. This monograph reports what is proven, what is contextualized, and where the boundaries lie.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Liraglutide is a prescription drug carrying a boxed warning and meaningful contraindications. Dosing figures are reported strictly as documented in FDA labeling and published trials, for completeness — not as recommendations. Consult a licensed clinician before starting, stopping, or changing any therapy.

What is liraglutide and how does it work?

Liraglutide is an acylated analog of human GLP-1, engineered to be 97 percent homologous to the native peptide by substituting arginine for lysine at position 34, with a C16 palmitic fatty-acid chain attached via a glutamic-acid spacer to the lysine at position 26.21 The molecular formula is C172H265N43O51 with a molecular weight near 3,751 Da.1

Mechanistically, liraglutide is a selective agonist at the GLP-1 receptor — a G-protein-coupled receptor expressed on pancreatic alpha and beta cells, the central and peripheral nervous systems, the heart, the lung and the gastrointestinal tract.2 Activation raises intracellular cyclic AMP, which drives four effects: glucose-dependent insulin secretion from beta cells, so insulin is released chiefly when glucose is elevated, limiting hypoglycemia; suppression of inappropriately high glucagon; slowing of gastric emptying; and central satiety and appetite suppression.21 The appetite and gastric effects are the principal drivers of weight loss; the insulin and glucagon effects drive glycemic control.

Native GLP-1 is degraded by dipeptidyl peptidase-4 within about two minutes. Liraglutide's structural modifications confer resistance to DPP-4 and neutral endopeptidases, and the palmitic acid drives reversible albumin binding (over 98 percent protein-bound), together extending the plasma half-life to roughly 13 hours and enabling once-daily dosing.21 Absolute subcutaneous bioavailability is about 55 percent, with peak plasma concentration at 8 to 12 hours; it is a peptide and is not orally bioavailable in this formulation.1

What is the evidence by indication?

Liraglutide's best-evidenced uses rest on large, multi-center phase 3 RCTs and a dedicated cardiovascular outcomes trial — together earning grade A. The table summarizes each indication and its strongest evidence.

For glycemic control, the pivotal evidence is the LEAD (Liraglutide Effect and Action in Diabetes) program — six phase 3 RCTs enrolling about 6,500 patients across more than 600 sites in 41 countries.3 In LEAD-3 monotherapy (52 weeks, n=746), HbA1c fell 0.84 percent (1.2 mg) and 1.14 percent (1.8 mg) versus 0.51 percent for glimepiride.4 LEAD-5 found liraglutide 1.8 mg superior to both placebo and insulin glargine as add-on therapy.5 Across the program, HbA1c reductions of roughly 0.8 to 1.5 percent are consistently reported, corroborated by real-world data.6

The most distinctive evidence is cardiovascular. LEADER was a dedicated randomized, double-blind, placebo-controlled outcomes trial of 9,340 high-risk type 2 diabetes patients, liraglutide up to 1.8 mg/day versus placebo on top of standard care for 3.5 to 5 years.7 The primary three-point MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 13.0 percent versus 14.9 percent — a 13 percent relative reduction (HR 0.87) — with a 22 percent reduction in cardiovascular death.7 The trial is registered as NCT01179048 and underpins the FDA's cardiovascular-risk-reduction indication.8

For weight management, the SCALE program assessed liraglutide 3.0 mg in 5,539 participants. In the pivotal SCALE Obesity and Prediabetes trial (56 weeks, n=3,731, no diabetes), mean weight loss was 8.0 percent versus 2.6 percent for placebo, with about 63 percent achieving at least 5 percent loss.9 SCALE Insulin showed 5.8 percent versus 1.5 percent loss in insulin-treated T2D.10 Pediatric approval rests on the ELLIPSE (T2D, age 10 and up) and SCALE Teens (obesity, ages 12 to 17) RCTs, where effect sizes are real but smaller than in adults.1112

What doses appear in the literature?

Reported strictly as documented in FDA labeling and trials — informational only, not a protocol. Liraglutide is given subcutaneously once daily, any time of day, independent of meals, into the abdomen, thigh or upper arm.1 For type 2 diabetes (Victoza), labeling describes 0.6 mg/day for the first week (to mitigate GI effects, not therapeutic), then 1.2 mg/day, with an option to increase to 1.8 mg/day if more control is needed.1 For obesity (Saxenda), the documented escalation is weekly: 0.6, then 1.2, 1.8, 2.4 and finally 3.0 mg/day as the maintenance dose.9 It is supplied as a pre-filled multi-dose pen (6 mg/mL) requiring no reconstitution.1 As a short-acting daily GLP-1, liraglutide is typically held roughly 24 to 48 hours before surgery or anesthesia, versus one to two weeks for weekly agents, per emerging perioperative guidance.21

How safe is liraglutide?

Liraglutide carries a boxed warning: it causes dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents at clinically relevant exposures, though human relevance is undetermined.116 This is a preclinical (animal) signal — grade C for the human carcinogenicity claim specifically — but it is treated as a hard contraindication out of caution, alongside a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, prior serious hypersensitivity, and pregnancy (Saxenda).1

The most common adverse events are dose-dependent and gastrointestinal — nausea, vomiting, diarrhea, constipation, dyspepsia and decreased appetite — and these are the leading cause of discontinuation.91 Serious warnings include acute pancreatitis (discontinue if suspected), acute gallbladder disease and cholelithiasis (risk rises with rapid weight loss), hypoglycemia when combined with insulin or sulfonylureas, a small heart-rate increase, acute kidney injury usually from GI-loss volume depletion, hypersensitivity including anaphylaxis, and a suicidal-ideation monitoring precaution added in 2017.116 Importantly, large RCTs and the LEADER outcomes trial have not confirmed an excess human cancer or pancreatitis risk at a population level — these remain monitored rather than established harms.7

What is the FDA and WADA status in 2026?

Liraglutide is a fully approved prescription drug — not a research chemical. Victoza was approved for type 2 diabetes in 2010 (with a cardiovascular-risk-reduction indication added after LEADER and a pediatric T2D indication for ages 10 and up), and Saxenda was approved for chronic weight management in 2014, with adolescents 12 to 17 added in December 2020.112 The major 2024-2025 development is generics: liraglutide is the first GLP-1 to go generic in the US. Teva launched the first generic liraglutide (Victoza reference) in June 2024, Hikma followed in December 2024, and Teva launched the first-ever generic GLP-1 indicated for weight loss (generic Saxenda) on August 29, 2025, priced about 30 percent below branded Saxenda.181719 These approvals were prioritized partly because branded liraglutide had been on the FDA drug-shortage list since 2023.20 Because approved generics now exist, liraglutide does not sit in the compounding gray zone that drove mass compounding of semaglutide and tirzepatide; it is also not a DEA-controlled substance.

For athletes, liraglutide and other GLP-1 receptor agonists are not on the WADA Prohibited List as of 2026, so they are legal in sport.22 However, semaglutide and tirzepatide were added to the WADA Monitoring Program for 2026 — a formal precursor to possible future prohibition — so athletes should confirm current status with their sport's anti-doping authority before use, since that status can change.22

How does liraglutide compare to newer agents?

Head-to-head, daily liraglutide is now generally outperformed on glucose and weight by once-weekly agents. In SUSTAIN 10 (n=577), once-weekly semaglutide 1.0 mg reduced HbA1c by 1.7 percent versus 1.0 percent for liraglutide 1.2 mg, and weight by 5.8 kg versus 1.9 kg, at the cost of more GI events.13 In obesity, STEP-8 showed semaglutide 2.4 mg achieved roughly 15.8 percent weight loss versus about 6.4 percent for liraglutide 3.0 mg.14 The mechanistic basis is pharmacokinetic: liraglutide's C16 acyl chain gives a roughly 13-hour half-life (daily dosing), whereas semaglutide's C18 diacid yields a far longer half-life and more sustained receptor activation.15

Bottom line. Liraglutide pairs a deep, coherent human RCT evidence base with genuine, disease-modifying cardiovascular benefit in the right patient — earning grade A and full regulatory approval. What is proven is real: HbA1c reduction, modest but reproducible weight loss, and reduced cardiovascular death in high-risk T2D. What is contextualized is that its glucose and weight effects are now second-tier to weekly semaglutide and tirzepatide, so its strongest present-day case is cost, daily-titration tolerability, perioperative flexibility, pediatric approval, and a standalone cardiovascular evidence base. Key uncertainties remain the (so-far unconfirmed in humans) thyroid C-cell signal, durability after discontinuation, and lean-mass loss. The boxed warning and contraindications are non-negotiable; this is prescription-only therapy requiring clinical oversight. Regulatory facts here are current as of June 2026 and should be re-verified for shortage-list and WADA status.